Development of a solid-phase assay for analysis of matrix metalloproteinase activity

Journal of Biomolecular Techniques

Volumn 15, Issue 4, 2004, Pages 305-316

  Lauer Fields, Janelle L ^a   Nagase, Hideaki ^b   Fields, Gregg B ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ELISA; Fluorogenic substrate; Matrix metalloproteinase; Melanoma; Solid phase assay

Indexed keywords

MATRIX METALLOPROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HUMAN; MELANOMA; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; MOLECULAR SEQUENCE DATA; SUBSTRATE SPECIFICITY;

EID: 21644462358     PISSN: 15240215     EISSN: 19434731     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Barrett AJ, Rawlings ND, Woessner JF. Handbook of Proteolytic Enzymes, 2nd ed, vol. 1. Amsterdam: Elsevier/ Academic Press; 2004.
2. Komsa-Penkova RS, Rashap RK, Yomtova VM. Advantages of orange-labelled collagen and gelatine as substrates for rapid collagenase activity measurement. J Biochem Biophys Methods 1997;34:237-249.
3. Cawston TE, Koshy P, Rowan AD. Assay of matrix metalloproteinases against matrix substrates. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:389-397.
4. Hembry RM. Detection of focal proteolysis using Texas- Red-gelatin. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Human Press, 2001:417-424.
5. Billington CJ. Cartilage proteoglycan release assay. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:451-456.
6. Zucker S, Mancuso P, DiMassimo B, Lysik RM, Conner C, Wu C-L. Comparison of techniques for measurement of gelatinases/type IV collagenases: Enzymelinked immunoassays versus substrate degradation assays. Clin Exp Metastasis 1994;12:13-23.
7. Gogly B, Groult N, Hornebeck W, Godeau G, Pellat B. Collagen zymography as a sensitive and specific technique for the determination of subpicogram levels of interstitial collagenase. Anal Biochem 1998;255:211-216.
8. Knauper V, Murphy G. Methods for studying activation of matrix metalloproteinases. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:377-387.
9. Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs and TIMPs. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:399-410.
10. George SJ, Johnson JL. In situ zymography. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:411-415.
11. Fujimoto N, Iwata K. Use of EIA to measure MMPs and TIMPs. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:p 347-358.
12. Fosang AJ, Last K, Jackson DC, Brown L. Antibodies to MMP-cleaved aggrecan. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:425-449.
13. Billinghurst RC, Ionescu M, Poole AR. Immunoassay for collagenase-mediated cleavage of types I and II colla gens. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:457-472.
14. Miller JA, Liu R-Q, Davis GL, Pratta MA, Trzaskos JM, Copeland RA. A microplate assay specific for the enzyme aggrecanase. Anal Biochem 2003;314:260-265.
15. Kashiwagi M, Enghild JJ, Gendron C, et al. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 2004;279:10109-10119.
16. Nagase H, Woessner JF, Jr. An improved assay for proteases and polysaccharides employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem 1980;107:385-392.
17. Nagase H, Fields GB. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers 1996;40:399-416.
18. Amour A, Slocombe PM, Webster A, et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998;435:39-44.
19. Fields GB. Using fluorogenic peptide substrates to assay matrix metalloproteinases. In: Clark IM (ed). Methods in Molecular Biology 151: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana Press, 2001:495-518.
20. Lauer-Fields JL, Kele P, Sui G, Nagase H, Leblanc RM, Fields GB. Analysis of matrix metalloproteinase activity using triple-helical substrates incorporating fluorogenic L- or D-amino acids. Anal Biochem 2003;321:105-115.
21. Nagase H, Fields CG, Fields GB. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J Biol Chem 1994;269:20952-20957.
22. Lauer-Fields JL, Sritharan T, Stack MS, Nagase H, Fields GB. Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem 2003; 278:18140-18145.
23. Minond D, Lauer-Fields JL, Nagase H, Fields GB. Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry 2004;43:11474-11481.
24. Lauer-Fields JL, Broder T, Sritharan T, Nagase H, Fields GB. Kinetic analysis of matrix metalloproteinase triplehelicase activity using fluorogenic substrates. Biochemistry 2001;40:5795-5803.
25. Lauer-Fields JL, Fields GB. Triple-helical peptide analysis of collagenolytic protease activity. Biol Chem 2002;383:1095-1105.
26. Malkar NB, Lauer-Fields JL, Borgia JA, Fields GB. Modulation of triple-helical stability and subsequent melanoma cellular responses by single-site substitution of fluoroproline derivatives. Biochemistry 2002;41: 6054-6064.
27. Lauer-Fields JL, Malkar NB, Richet G, Drauz K, Fields GB. Melanoma cell CD44 interaction with the a1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycoslyation. J Biol Chem 2003;278:14321-14330.
28. Baronas-Lowell D, Lauer-Fields JL, Borgia JA, et al. Differential modulation of human melanoma cell metalloproteinase expression by α2α1 integrin and CD44 triple-helical ligands derived from type IV collagen. J Biol Chem 2004;279:43503-43513.
29. Chung L, Shimokawa K, Dinakarpandian D, Grams F, Fields GB, Nagase H. Identification of the RWTNNFREY(183-191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem 2000;275:29610-29617.
30. Huang W, Suzuki K, Nagase H, Arumugam S, Van Doren S, Brew K. Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett 1996;384:155-161.
31. Hurst DR, Schwartz MA, Ghaffari MA, et al. Catalyticand ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem J 2004;377:775-779.
32. Malkar NB, Lauer-Fields JL, Juska D, Fields GB. Characterization of peptide-amphiphiles possessing cellular activation sequences. Biomacromolecules 2003;4:518-528.
33. Baronas-Lowell D, Lauer-Fields JL, Fields GB. Induction of endothelial cell activation by a triple-helical α2b1 integrin ligand derived from type I collagen α1(I)496-507. J Biol Chem 2004;279:952-962.
34. Woessner JF, Nagase H. Matrix Metalloproteinases and TIMPs. Oxford: Oxford University Press, 2000.
35. Toth M, Hernandez-Barrantes S, Osenkowski P, et al. Complex pattern of membrane type I matrix metalloproteinase shedding. J Biol Chem 2002;277:26340-26350.
36. Crowther JR. ELISA: Theory and Practice. Totowa, NJ: Humana Press, 1995.
37. Lauer-Fields JL, Nagase H, Fields GB. Use of Edman degradation sequence analysis and matrix-assisted laser desorption/ionization mass spectrometry in designing substrates for matrix metalloproteinases. J Chromatogr A. 2000;890:117-125.
38. Tamei H, Azumano I, Iwata K, et al. One-step sandwich enzyme immunoassays for human matrix metalloproteinase 13 (collagenase-3) using monoclonal antibodies. Connect Tissue 1998;30:15-22.
39. Maliszewska M, Mader M, Scholl U, et al. Development of an ultrasensitive enzyme immunoassay for the determination of matrix metalloproteinase-9 (MMP-9) levels in normal human cerebrospinal fluid. J Neuroimmunol 2001;116:233-237.
40. Okada Y, Nagase H, Harris ED, Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. J Biol Chem 1986;261:14245-14255.
41. Wilhelm SM, Shao ZH, Housley TJ, et al. Matrix metalloproteinase- 3 (stromelysin-1). J Biol Chem 1993;268: 21906-21913.
42. Giambernardi TA, Sakaguchi AY, Gluhak J, et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biol 2001;20:577-587.
43. Ntayi C, Lorimier S, Berthier-Vergnes O, Hornebeck W, Bernard P. Cumulative influence of matrix metalloproteinase- 1 and -2 in the migration of melanoma cells within three-dimensional type I collagen lattices. Exp Cell Res 2001;270:110-118.
44. Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. BioEssays 1999;21: 940-949.
45. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a threedimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000; 149:1309-1323.
46. Seiki M. Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Lett 2003; 194:1-11.
47. Knutson JR, Iida J, Fields GB, McCarthy JB. CD44/chondroitin sulfate proteoglycan and α2b1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 1996;7:383-396.
48. Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci 2004;117:373-380.
49. Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-17131.
50. Vogel WF. Collagen-receptor signaling in health and disease. Eur J Dermatol 2001;11:506-514.
51. Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589-4592.
52. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol 2000;19:319-323.
53. Yu Y-C, Pakalns T, Dori Y, McCarthy JB, Tirrell M, Fields GB. Construction of biologically active protein molecular architecture using self-assembling peptideamphiphiles. Meth Enzymol 1997;289:571-587.
54. Lauer JL, Gendron CM, Fields GB. Effect of ligand conformation on melanoma cell α3b1 integrin-mediated signal transduction events: Implications for a collagen structural modulation mechanism of tumor cell invasion. Biochemistry 1998;37:5279-5287.
55. Fields GB, Lauer JL, Dori Y, Forns P, Yu Y-C, Tirrell M. Proteinlike molecular architecture: Biomaterial applications for inducing cellular receptor binding and signal transduction. Biopolymers 1998;47:143-151.
56. Dori Y, Bianco-Peled H, Satija SK, Fields GB, McCarthy JB, Tirrell M. Ligand accessibility as a means to control cell response to bioactive bilayer membranes. J Biomed Mater Res 2000;50:75-81.
57. Hostikka SL, Tryggvason K. The complete primary structure of the α2 chain of human type IV collagen and comparison with the α1(IV) chain. J Biol Chem 1988;263:19488-19493.